IN8bio reports promising lupus treatment data

NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical firm focused on gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, presented new preclinical data for its INB-619 program at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The findings indicate that INB-619, a CD-19 targeted γδ T cell engager (TCE), successfully eliminated disease-causing B cells in blood samples from patients with active Systemic Lupus Erythematosus (SLE, or Lupus).

The company’s research suggests that INB-619 can deplete harmful B cells that contribute to autoimmune diseases without provoking severe inflammatory side effects, such as cytokine release syndrome (CRS). This marks a significant departure from traditional TCEs that target CD3 and are known to trigger such adverse reactions. According to InvestingPro data, IN8bio maintains a strong liquidity position with a current ratio of 4.3, indicating robust short-term financial stability despite ongoing R&D investments.

William Ho, Chief Executive Officer of IN8bio, stated, "Our findings show that INB-619 not only eliminates pathogenic B cells, but also expands γδ T cell levels, which are often reduced in patients with chronic disease." He emphasized that this approach could lead to safer and more effective treatments for autoimmune conditions.

The preclinical data showcased the complete, targeted depletion of B cells in lupus patient-derived samples and the expansion of both Vδ1+ and Vδ2+ subtypes of γδ T cells, essential for targeting both circulating and tissue-resident B cells for potentially deeper B cell depletion. Notably, INB-619 did not cause significant release of inflammatory cytokines such as IL-6, commonly associated with serious toxicities including CRS.

The study reinforces the potential of γδ T cell engagers as a safer, more precise immunotherapy platform for autoimmune diseases. IN8bio is exploring potential partnerships and additional autoimmune and cancer indications where γδ T cell biology and B cell targeting intersect. While the company holds more cash than debt on its balance sheet, InvestingPro analysis reveals rapid cash consumption, with analysts not expecting profitability this year. Get access to 8 more key ProTips and detailed financial metrics with an InvestingPro subscription.

IN8bio’s lead program, INB-100, is focused on acute myeloid leukemia, evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The company is also advancing novel γδ T cell engagers for potential oncology and autoimmune indications.

This article is based on a press release statement from IN8bio, Inc.

In other recent news, IN8bio, Inc. announced promising Phase 1 trial results for its INB-100 therapy targeting acute myeloid leukemia (AML). The trial data showed no relapses among patients treated with INB-100, with a 1-year progression-free survival rate of 90.9% and an overall survival rate of 100%. This development could potentially change post-transplant care in hematologic oncology. Additionally, H.C. Wainwright maintained its Buy rating on IN8bio but lowered the price target from $8.00 to $6.00 following a recent capital raise. The firm cited the dilutive effect of the capital raise as a reason for the adjustment but retained a positive long-term outlook. Furthermore, IN8bio announced the resignation of Travis Whitfill from its Board of Directors, effective May 9, 2025. His departure is not linked to any disagreements with the company’s operations or policies. These recent developments reflect ongoing changes and progress within IN8bio’s operations and strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.